Strategic and Tactical Competitive Insights
We deliver crucial insights that empower clients to make winning strategic decisions.
Our consulting uncovers threats/opportunities, empowering clients to make strategic decisions that yield winning outcomes.
We deliver evidence-based recommendations, informed by expert interviews, to help clients address issues across:
- Asset Clinical Development and Commercialization
- R&D and Pipeline Assets
- Market Access
- Pricing/Reimbursement
- Regulatory Needs
- Emerging Markets
- Biosimilars/Generics
- OTC Offerings
- Digital Health
We provide decision support across the product lifecycle:
- New Product Planning
- Brand Planning
- Mature Product Planning
Our research capabilities are bolstered by in-house experts and a network spanning:
- Oncology/Hematology (solid/liquid tumors etc.)
- Gene and Cell Therapy / Rare Diseases (muscular dystrophy, ophthalmology, hemophilia etc.)
- Inflammatory and Autoimmune Diseases (including rheumatology, dermatology, allergy, MS etc.)
- Neurological Disorders (including epilepsy, Alzheimer’s, schizophrenia, PD etc.)
- Respiratory Disorders (including asthma, COPD, IPF, PAH etc.)
- Cardiovascular Disorders / Diabetes (including stroke, lipid disorders etc.)
- Infectious Diseases / Vaccines (including HIV, HCV, flu, MRSA, RSV etc.)
- Pain (including chronic pain, cancer-associated pain etc.)
- Blood Disorders (e.g. hemophilia)
With timely insights across therapy areas, we equip clients to accelerate competitive advantage.
Ready to build winning competitive strategies?
Let’s accelerate your success together. Contact us at info@lqventures.com.
January 8, 2026
Immunology Today—January 8, 2026
January 8, 2026
Cell and Gene Therapy Video Recap—January 8, 2026
January 8, 2026
Cell and Gene Therapy Today—January 8, 2026
January 8, 2026
AI in Healthcare and Digital Health Today—January 8, 2026
January 8, 2026
Lucid Diligence Brief: Lilly to acquire Ventyx Biosciences
January 7, 2026
Women’s Health Video Recap—January 7, 2026
January 7, 2026
Neuroscience Video Recap—January 7, 2026
January 7, 2026
Neuroscience Today — January 7, 2026
January 7, 2026
Lucid Diligence Brief: Amgen acquires Dark Blue Therapeutics
January 5, 2026
Lucid Diligence Brief: Insilico Medicine × Servier oncology collaboration
January 5, 2026